A LEAN MEAN FIGHTING MACHINE!!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Happy Easter to all. e/m
PRKR, They cut there losses by a third pps. But I found this retraction in a pr....bummer. But the charts look great.
Correction: ParkerVision 4Q results story
The Associated Press
JACKSONVILLE, Fla. —
In a story March 15 about ParkerVision Inc.'s fourth-quarter results, The Associated Press reported erroneously that the company recorded revenue of $64 million. Its revenue was $64,000.
http://seattletimes.nwsource.com/html/businesstechnology/2011358859_apusearnsparkervisioncorrective.html
I do not own this at this time.
PRKR my Augusta Masters play chart and short info.
FYI the fundies look bad for near termimo
ParkerVision Inc.
$ 1.91
PRKR
0.21
Short Interest (Shares Short)
5,090,600
Days To Cover (Short Interest Ratio)
21.7
Short Percent of Float
15.01 %
Short Interest - Prior
5,164,300
Short % Increase / Decrease
-1.43 %
Short Squeeze Ranking™
28
% From 52-Wk High ($ 4.90 )
-156.54 %
% From 52-Wk Low ($ 1.41 )
26.18 %
% From 200-Day MA ($ 2.63 )
-37.70 %
% From 50-Day MA ($ 1.88 )
1.57 %
Price % Change (52-Week)
8.50 %
Shares Float
33,924,849
Total Shares Outstanding
41,192,550
% Owned by Insiders
11.00 %
% Owned by Institutions
52.20 %
Market Cap.
$ 78,677,771
Trading Volume - Today
370,658
Trading Volume - Average
234,200
Trading Volume - Today vs. Average
158.27 %
Earnings Per Share
-0.65
PE Ratio
Record Date
2010-MarB
Sector
Technology
Industry
Semiconductor - Integrated Circuits
Exchange
NAS
PRKR my Augusta Masters play chart and short info.
FYI the fundies look bad for near term
imo
ParkerVision Inc.
$ 1.91
PRKR
0.21
Short Interest (Shares Short)
5,090,600
Days To Cover (Short Interest Ratio)
21.7
Short Percent of Float
15.01 %
Short Interest - Prior
5,164,300
Short % Increase / Decrease
-1.43 %
Short Squeeze Ranking™
28
% From 52-Wk High ($ 4.90 )
-156.54 %
% From 52-Wk Low ($ 1.41 )
26.18 %
% From 200-Day MA ($ 2.63 )
-37.70 %
% From 50-Day MA ($ 1.88 )
1.57 %
Price % Change (52-Week)
8.50 %
Shares Float
33,924,849
Total Shares Outstanding
41,192,550
% Owned by Insiders
11.00 %
% Owned by Institutions
52.20 %
Market Cap.
$ 78,677,771
Trading Volume - Today
370,658
Trading Volume - Average
234,200
Trading Volume - Today vs. Average
158.27 %
Earnings Per Share
-0.65
PE Ratio
Record Date
2010-MarB
Sector
Technology
Industry
Semiconductor - Integrated Circuits
Exchange
NAS
It looks like this was already posted a couple days ago. it was listed as todays news. I hate it when old news is re-released.
NOVAVAX RELEASES FINAL RESULTS FROM ITS TRIVALENT SEASONAL INFLUENZA VACCINE PHASE II CLINICAL STUDY
Thursday, 01 April 2010
Novavax, Inc. a clinical-stage vaccine company, released the final results from a Phase II clinical trial evaluating Novavax's trivalent seasonal influenza Virus-like particle (VLP) vaccine candidate in healthy adults. The study enrolled healthy volunteers 18 to 49 years in age who were immunized with a single injection of Novavax's trivalent seasonal influenza VLP vaccine matched to the influenza strains recommended for the 2008-2009 influenza vaccine. Preliminary data from this trial were reported in 2009.
The complete analysis included 232 volunteers in total; with 49 receiving placebo, 83 given Novavax's trivalent seasonal influenza VLP vaccine at 15 mcg/dose, 81 injected with Novavax's trivalent seasonal influenza VLP vaccine at 60 mcg/dose and 19 volunteers receiving an inactivated trivalent influenza vaccine Fluzone® (TIV) at 15 mcg/dose. The three strains were H1N1 A/Brisbane/59/2007, H3N2 A/Brisbane/10/2007, and B/Florida/04/2006. The data show that Novavax's trivalent seasonal influenza VLP vaccine induced a robust hemagglutination inhibition (HAI) antibody response against all three strains in the vaccine. Seroconversion rates as defined by the FDA (including lower and upper 95% Confidence Intervals (CI)) for the 15 mcg group were as follows: 51% (39, 62), 76% (65, 85), and 58% (47, 69) against the H1N1, H3N2, and B strains, respectively. Seroprotection (titer greater than or equal to 1:40) rates for volunteers in the 15 mcg group (with 95% CIs) were 70% (59, 80), 89% (80, 94), and 84% (75, 91) against the H1N1, H3N2, and B strains, respectively.
Preliminary HAI results from this study were presented at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) on October 31, 2009 and were described in a company press release dated November 2, 2009. Those interim results were based on evaluation of a total of 190 volunteers, of which 37 received placebo, 69 received trivalent seasonal influenza VLP vaccine at 15 mcg/dose, 67 received trivalent seasonal influenza VLP vaccine at 60 mcg/dose and 17 received TIV. For volunteers in the 15 mcg group, seroconversion rates (greater than or equal to 4-fold rise in titer from baseline) with the accompanying 95% CI were 57% (44, 68), 86% (75, 93), and 62% (50, 74) against the H1N1, H3N2, and B strains, respectively. For volunteers in the 15 mcg group, seroprotection rates (titer greater than or equal to 1:40) with 95% CI were 67% (54, 78), 91% (82, 97), and 84% (73, 92) against the H1N1, H3N2, and B strains, respectively. In the final results reported today, the H3N2 and B strain data in the 15 mcg VLP dose met the FDA seroconversion guidelines of 40 (lower 95% CI) while the H1N1 data fell just short (39.4 versus 40.0). However, the mean seroprotection rate against the H1N1 strain rose slightly from an original 67% to a final 70%.
In addition to the HAI titers, functional antibody against the Neuraminidase enzyme was measured in the sera of immunized subjects using a neuraminidase inhibition assay (NAI). Inhibition of neuraminidase activity may be important in reducing the spread and severity of influenza infection. Novavax tested volunteers for NAI against B/Florida, H3N2/Brisbane and H1N1/Brisbane components of the vaccine before and after immunization. Against the B strain, 59% of the patients receiving the 15 mcg dose of VLP showed a 4-fold or higher rise in NAI titers over pre-immune levels. At the 60 mcg VLP dose, 73% had a 4-fold rise while only one subject (5%) from the TIV population had a 4-fold rise. In the NAI assay against the H3N2 strain, 50% of the patients immunized with the 15 mcg VLP dose had a 4-fold rise in NAI titers. At the 60 mcg VLP dose, 56% had a 4-fold rise. In the small subset of subjects tested against H1N1 NAI activity (10 placebo and 20 at the 60 mcg VLP dose), the NAI in the VLP treated group increased about 30% over preimmunization levels while the placebo treated group had no increase over pre-immunization levels.
"The data released today show that our VLP influenza vaccine not only induces a robust HAI response but also enhances the NAI response far above that induced by TIV," said Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax. "We will continue measurement of NAI activity in other clinical trials since we believe that the ability of the VLP vaccine to elicit an NAI response may differentiate our vaccine from others. These NAI results support our position that VLP influenza vaccines have the potential to induce a broad-based immune response that could lead to improved clinical outcomes. We now await comparative immunological and safety data from a larger head to head clinical trial in older adults (>60 years of age) between TIV and our VLP vaccine," said Dr. Singhvi.
About VLPs
Virus-like particles (VLPs) mimic the external structure of viruses but lack the live genetic material that causes viral replication and infection. VLPs can be designed quickly to match individual viral strains and be produced efficiently using portable cell-culture technology. Novavax VLP-based vaccine candidates are produced more rapidly than egg-based vaccines by using proprietary, portable, recombinant cell-culture technology.
About Novavax
Novavax, Inc. is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP -based, recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. It launched in 2009 a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.
Forward-Looking Statements
Statements herein relating to future performance, conditions or strategies and other matters, including expectations regarding clinical trials, release of new data, continued development of the seasonal vaccine and its potential differentiation, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include historical and current results may not be predictive of future trial results for the seasonal vaccine or any other vaccine that we are developing or may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if the results are similar or better than the results reported to date; uncertainties related to the initiation, enrollment, progress and completion of clinical trials; safety or efficacy issues not seen to date may be encountered; the market or industry experts may not accept that our neuraminidase results show a differentiation of our vaccine from other vaccines; the immune systems of the elderly pose significant challenges for vaccines and our products may not be as efficacious in the elderly as they have been in test subjects to date; the Company has not yet manufactured, or relied on third parties to manufacture, any vaccines at a commercial scale; and the seasonal flu vaccine industry is intensely competitive, making it difficult for our vaccine to have market success even if approved. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.
Source: Novavax, Inc.
http://pr-canada.net/index.php?option=com_content&task=view&id=180973&Itemid=59
The ad-hoc committee is the group fighting for that. The B.O.D. has even more going against them. imo
Thanks for posting that. What a day.
April 13th is the court date, i bought back in yesterday. I think it will climb until court day. I am freeing up funds for that verdict. If it goes in favor of the common share holder (which is possible). BOOM!! Past the moon to PLUTO, that or 10 bucks . imo
And today.
April 1 (Reuters) - Unsecured creditors of bankrupt auto parts maker Visteon Corp <VSTNQ.PK> have asked the court to terminate the company's exclusivity, or the period in which it has the sole right to propose a restructuring plan.
The official committee of unsecured creditors said in a filing on Wednesday that Visteon had again solely aligned itself with its term lenders in the latest amended reorganization plan and that the committee was looking to support alternative plans to maximize its recovery.
"Competing plans are poised to be filed, and should be parallel-tracked. The official committee could be a proponent of the rights offering plan or submit a plan predicated on reinstatement (partially, or in full) of the term loan," the unsecured creditors said.
Term loans would be rendered unimpaired under both these alternative plans and would be eliminated as a voting class, they said.
The timing of the filing of the amended plan seems designed to give it an unfair head start, which will likely lead to a protracted confirmation battle, the committee said.
The committee added that terminating exclusivity and tracking plans side by side promotes an efficient reorganization rather than allowing Visteon and its term lenders' amended plan having a head start.
The latest plan converts the company's $1.629 billion secured debt to 85 percent of the company's equity. Holders of Visteon's 12.25 percent senior notes would receive 6 percent of the company's equity and the remaining equity would be distributed among holders of other unsecured notes and non-trade claims.
Visteon, which was spun off from Ford in 2000, filed for bankruptcy protection last June. It was one of the biggest casualties of the global auto industry crisis that forced General Motors Corp [GM.UL] and Chrysler to restructure in bankruptcy court and saddled other automakers and suppliers with mounting losses.
It relies on Ford for nearly 30 percent of its sales.
The case is In re Visteon Corp, U.S. Bankruptcy Court, District of Delaware, No. 09-11786. (Reporting by Santosh Nadgir in Bangalore; Editing by Jarshad Kakkrakandy)
bought back in.
(last post of day)CHCI-Comstock Homebuilding Reports Profitable Fourth Quarter, Marking the Second Consecutive Profitable Quarter
Comtex
RESTON, VA, Mar 31, 2010 (MARKETWIRE via COMTEX) ----Comstock Homebuilding Companies, Inc. (NASDAQ: CHCI) ("Comstock" or the "Company") today released audited financial results for fiscal 2009 in which the Company's independent auditors have removed the explanatory paragraph with respect to the Company's ability to continue as a going concern from their audit opinion. The Company also announced net income for its fourth quarter ended December 31, 2009 of $1.4 million, $0.07 diluted income per share, compared to a net loss of $4.8 million and diluted loss per share of $0.27 for the fourth quarter of 2008. Total revenue for the fourth quarter of 2009 was $4.0 million compared to total revenue of $5.2 million for the comparable 2008 quarter.
For the year ended December 31, 2009, total revenue was $25.1 million, compared to total revenue of $46.7 million for the year ended December 31, 2008. Net loss for the year ended December 31, 2009 was $26.8 million, primarily as a result of losses reported in the first half of 2009, as compared to a net loss of $17.1 million for the year ended December 31, 2008. Diluted loss per share for the year ended December 31, 2009 was $1.51 compared to a diluted loss per share of $0.98 for 2008.
In an effort to stabilize the Company, management formulated its Strategic Realignment Plan (the "Plan") and spent much of 2009 negotiating with lenders to eliminate and restructure debt in order to reposition the Company with an improved balance sheet and an enhanced ability to pursue new opportunities as market conditions improve. As a result of the Plan, the Company has reduced debt from $340.0 million in mid 2006, to $102.8 million at December 31, 2008 and to $67.6 million at December 31, 2009.
Results of Operations
http://www.foxbusiness.com/story/markets/industries/real-estate/comstock-homebuilding-reports-profitable-fourth-quarter-marking-second/
Added here. e/m
CDIV nice day!
ARQL out 6.90, covered my costs and a lil' more. Volume slowed and I am going to the GYM. C-ya
as I wrote this it jumped to 7, hell i sold it'll probably go to 400 by the time I get back. lol
ARQL small float is giving me LARGE STRESS. The large dips and surges. SHEESH!!
Shares Float
44,412,405
Total Shares Outstanding
44,726,321
% Owned by Insiders
0.60 %
% Owned by Institutions
57.90 %
So apx 25 million in the float?
Could this go Hostile while in bk court? What do you think Kemper does next. They are not going down without a fight imo.
ARQL, good size buys coming through here. Could have legs for eight bucks today. imo
ARQL going for 7. Next stop 7.64 My bust I missed the 7.40ish resistance on the 4 year chart. lol
ARQL could be the play today. Watching for an entry.
edit*** in at $6.50***
Rig is a much better pick than I. GLTY
ARQL CC is going on now, a lot of medical terms over my head but I am getting most of it.
Date: Wednesday, March 31, 2010
Time: 8:30 a.m., Eastern Time
Conference Call Numbers
Domestic: (877) 868-1831
International: (914) 495-8595
www.arqule.com
ARQL up 65% pm.NICE FIND. Chart/News below.
ArQule, Inc. Announces Results Of Phase II Trial With ARQ 197 In Advanced Non-Small Cell Lung Cancer
7:00am EDT
ArQule, Inc. announced that ARQ 197, when used in combination with erlotinib, demonstrated a 66% improvement in median Progression-Free Survival (PFS) in patients with advanced, refractory non-small cell lung cancer (NSCLC). In the intent to treat (ITT) population (n = 167), median PFS was 16.1 weeks in the ARQ 197 plus erlotinib arm, compared with 9.7 weeks in the erlotinib plus placebo arm. The difference in PFS between the two arms did not achieve statistical significance (hazard ratio = 0.809) by applying a log-rank test. When adjusting for imbalances in the distribution of key prognostic factors, the difference in PFS was statistically significant (hazard ratio = 0.675) by applying a Cox regression analysis specified for secondary efficacy analyses. Improvement in median PFS was more pronounced in the pre-defined sub-group of patients with non-squamous histology (n = 117); median PFS was 18.9 weeks in the treatment arm versus 9.7 weeks in the control arm, which represents a 94% improvement. Based on an exploratory Cox regression analysis, the endpoint of PFS was met in the sub-group and achieved statistical significance (hazard ratio = 0.613). There were no clinically relevant differences in adverse event rates between the treatment and control arms. The majority of adverse events were mild in intensity and included rash, diarrhea and fatigue.
MBTG- I agree on the run part, but disagree on the defensive part. Come on 2 BILLION shares? On a company with a market cap of 4.6 MILLION bucks. Why not 750 million or 1 billion why not leave it at 400 million? And the mention of a reverse at there discretion. I agree it can run but I wouldn't hold it over night. But hey that's just me and I have been wrong before. GLTY
I am not keeping current here. I sold at 7.30 and 5.70.
MBTG - I just don't like this part. It may become a dilution machine. I'll watch it though.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7135269
Item 5.07 Submission of Matters to a Vote of Security Holders.
Item 8.01 Other Events.
We held a Special Meeting of Stockholders on March 12, 2010. At the meeting, stockholders approved the following:
1. Amendment of our Certificate of Incorporation to increase the number of authorized shares of Common Stock from 400,000,000 to two billion:
Common Stockholders’ Vote:
Votes in Favor
Votes Against
Votes Abstained
210,990,919
11,418,416
242,878
All Stockholders’ Vote:
Votes in Favor
Votes Against
Votes Abstained
914,173,962
14,285,566
242,878
2. (a) a possible reverse stock split of our outstanding shares of common stock in an amount which our board of directors deems appropriate to be at a ratio of not less than one-for-forty and not more than one-for-eighty; and (b) the filing of an amendment to our certificate of incorporation effecting the foregoing, at such time as our board of directors determines:
Votes in Favor
Votes Against
Votes Abstained
916,182,655
12,114,131
405,620
3. Amendment of our Certificate of Incorporation to change ouor name from Millennium Biotechnologies Group, Inc. to Inergetics, Inc.:
Votes in Favor
Votes Against
Votes Abstained
906,719,212
10,135,785
11,847,410
On March 15, 2010, we filed an amendment to our amended and restated certificate of incorporation changing our name from Millennium Biotechnologies Group, Inc. to Inergetics, Inc. and increasing the number of authorized shares of our common stock from 400,000,000 to two billion.
A copy of the press release, dated March 17, 2010 related to the meeting results is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
LMAO,My cocktail almost came out my Nose!! Also the chart is SOLID
AEN, what's top? Man, she won't stop. I think I missed it then BAM up 25% more. WTF?
AGEL .0002 e/m
WHRT I don't much like that gap, but other than that the chart looks nice. You think back to the 8's?
i sold my $7's at 7.30, still have my 5's. I would like to see it run up to that 7.05 resistance again. Have to see how the rest of the day goes. :-/
i would prefer .0005. it's a start.
ABIO looks like the shorts won. e/m
AGEL Angels in Action: Meets With Online Retailing Group -- Seeks Collaborative Partnerships
March 29, 2010: 09:54 AM ET
Angel Acquisition Corp (OTCBB: AGEL) is pleased to announce that its micro-lending and peer-to-peer social lending network is actively developing collaborative retail partnerships. (www.angelsinaction.tv).
The company is in discussion and looks to formally sign and announce the following contract within the near term:
a. Online Retailing Group: the company met last week with the management team of an online retail group. The intention of the discussions is to form up a revenue sharing partnership whereby a portion of each sale processed would migrate forward to initiate micro-loans via Angels in Action (www.angelsinaction.tv)
b. Angels in Action Online Merchant Partnerships: the company is actively seeking online retail partnerships and other collaborative ventures. If you, or your company operates an online portal that actively sells, markets and processes commerce, and you would be interested in discussing a partnership, please contact the company directly. (The company will not entertain any discussions with groups that operate pornographic and/or adult genre products).
With these expanded online sales and revenue options, the company expects to accelerate the deployment of Angels in Action (www.angelsinaction.tv) via these planned and now emerging strategic partnerships. Angels in Action is poised to serve the estimated 28 Million un-banked and under-banked individuals thru its micro-lending and peer-to-peer lending efforts. The company will update its shareholders on these and other key business advances as formal contracts are completed.
From time to time, the Company may issue news releases that contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbor created by those sections. This material may contain statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. For those statements, the Company claims the protection of the safe harbor for forward-looking statement provisions contained in the Private Securities Litigation Reform Act of 1995 and any amendments thereto. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be 'forward-looking statements.' 'Forward-looking statements' are based upon expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those anticipated.
Contact:
Investor Relations contact@angelacquisitions.com
1-775-887-0670
Shorts are winning. I wonder if the MM's just wanted to hit below 7 to fill the stop losses. hmmmm? need some buys.
Let's hope for a good Monday. Lots of attention on all the trader blogs.
I agree there were no more shares to Short by eod Friday, I just do not believe there are 8.9 million currently Short. I do believe people shorted Friday, got burned, sold and went long or left all together. And that is reflected in that number. Look at griff100 on Langlui's board, who then went long. I think the bigger picture is a possible buy-out at a much, MUCH higher pps.
Posted by: griff100 Member Level Date: Friday, March 26, 2010 11:55:09 AM
In reply to: glassy who wrote msg# 91762 Post # of 91878
I shorted ABIO 7.95 and 8.95...I'm skeeeered!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=48293073
GLTA
I have no disagreement there. I was stating what the float was. I am holding for bigger bucks also. So yes the float could be 3 million if not lower, including the people who got in Friday and are holding for more. And Monday will be interesting. We could see a dip/manipulation for the naked shorts trying to cover also. But yes upwards and onwards.
Thanks for the info. e/m
Also that short number is misleading. That is the "Aggregate reported share volume of executed short sale trades during regular trading hours." http://regsho.finra.org/DailyShortSaleVolumeFileLayout.pdf
So every body that closed their short positions many times over are included in that number. It isn't the current number outstanding. So out of the nearly 50 million traded 8 million were short. A lot of flippers today, long to short to long. Considering there are only 7.6 million shares o/s, it makes sense. I am probably telling you what you already know. If so I apologize. And hell, who knows how many kept there short position yesterday?
GLTY, GO ABIO!!!